TX200

Cell therapy

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Kidney Transplant Rejection Prophylaxis

Competitive landscape

This drug's own stage for Kidney Transplant Rejection Prophylaxis: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
TX200: this drugPhase 1/2Cell therapyHLA-A*02 (CAR-Treg)not yet gradedNo reviewed efficacy summary in this indication
Basiliximab (Simulect)ApprovedMonoclonal antibodyIL-2 receptor alpha (IL2RA)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.